Series A financing disclosure · Biotech

Seawolf Therapeutics discloses Series A as it emerges from stealth

The company reported $100m across seed and Series A financing without disclosing the amount of either round.

Seawolf Therapeutics disclosed Series A financing on 16 November 2026, backed by Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. Its $100 million funding total includes an earlier seed round; the individual allocations were not disclosed. The company will advance DNA medicines using its TRIDENT delivery platform. A separate Sanofi collaboration carries potential milestones of up to $1.2 billion and royalties, rather than investment proceeds.

Use of funds

Advance DNA-delivery therapeutics using TRIDENT

Develop a lead metabolic-disease program

Funding history

Series A financing disclosure · This roundUndisclosed

Sources

  1. Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeuticsseawolftx.com · Nov 16, 2026